Skip to main content

Compare Stocks

Date Range: 

 AtrecaInozyme PharmaApplied TherapeuticsSelecta BiosciencesFoghorn Therapeutics
SymbolNASDAQ:BCELNASDAQ:INZYNASDAQ:APLTNASDAQ:SELBNASDAQ:FHTX
Price Information
Current Price$9.82$15.85$15.87$3.00$9.87
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.71.81.61.5
Analysis Score3.53.53.53.43.5
Community Score2.62.82.22.23.6
Dividend Score0.00.00.00.00.0
Ownership Score1.71.72.51.70.0
Earnings & Valuation Score0.60.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$29.33$36.00$54.67$7.20$24.67
% Upside from Price Target198.71% upside127.13% upside244.47% upside140.00% upside149.92% upside
Trade Information
Market Cap$361.68 million$372.06 million$412.80 million$339.58 million$363.48 million
Beta0.08N/A1.271.18N/A
Average Volume241,65057,371114,5041,634,40994,622
Sales & Book Value
Annual RevenueN/AN/AN/A$6.68 millionN/A
Price / SalesN/AN/AN/A50.84N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.68 per shareN/AN/A$0.10 per shareN/A
Price / BookN/AN/AN/A30.00N/A
Profitability
Net Income$-67,480,000.00N/A$-45,510,000.00$-55,350,000.00N/A
EPS($4.26)N/A($3.55)($1.22)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-43.21%N/A-85.39%N/AN/A
Return on Assets (ROA)-40.98%N/A-70.42%-54.69%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio28.48%16.71%5.99%2.16%N/A
Quick Ratio28.48%16.71%5.99%2.16%N/A
Ownership Information
Institutional Ownership Percentage69.64%69.77%54.25%56.92%N/A
Insider Ownership Percentage9.90%N/A31.50%22.40%N/A
Miscellaneous
Employees13038244395
Shares Outstanding36.83 million23.47 million26.01 million113.19 million36.83 million
Next Earnings Date5/13/2021 (Estimated)6/24/2021 (Estimated)8/10/2021 (Estimated)5/13/2021 (Confirmed)N/A
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Foghorn Therapeutics Appoints Ian Smith to its Board of DirectorsFoghorn Therapeutics Appoints Ian Smith to its Board of Directors
finance.yahoo.com - April 28 at 9:35 AM
Foghorn Therapeutics, Inc. (FHTX)Foghorn Therapeutics, Inc. (FHTX)
realmoney.thestreet.com - April 22 at 11:58 PM
Foghorn Therapeutics Inc (FHTX)Foghorn Therapeutics Inc (FHTX)
investing.com - April 14 at 7:16 AM
Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?
finance.yahoo.com - April 1 at 1:59 PM
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
finance.yahoo.com - March 24 at 12:29 PM
FHTX Stock Price Increased 36.61%: Why It HappenedFHTX Stock Price Increased 36.61%: Why It Happened
pulse2.com - March 21 at 1:54 PM
Foghorn Therapeutics Provides Corporate UpdateFoghorn Therapeutics Provides Corporate Update
finance.yahoo.com - March 18 at 9:51 AM
Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
apnews.com - March 12 at 9:40 PM
Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
finance.yahoo.com - March 11 at 8:31 PM
UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021
finance.yahoo.com - March 11 at 8:31 PM
Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare ConferenceFoghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference
finance.yahoo.com - February 22 at 1:00 PM
Foghorn Therapeutics Inc. (FHTX)Foghorn Therapeutics Inc. (FHTX)
finance.yahoo.com - February 2 at 12:35 AM
What Is The Ownership Structure Like For Foghorn Therapeutics Inc. (NASDAQ:FHTX)?What Is The Ownership Structure Like For Foghorn Therapeutics Inc. (NASDAQ:FHTX)?
finance.yahoo.com - January 23 at 12:50 PM
Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateFoghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - December 4 at 8:10 AM
Foghorn Therapeutics Inc. Common Stock (FHTX)Foghorn Therapeutics Inc. Common Stock (FHTX)
nasdaq.com - November 23 at 5:33 PM
Foghorn Therapeutics Rings the Opening Bell in Celebration of its IPOFoghorn Therapeutics Rings the Opening Bell in Celebration of its IPO
nasdaq.com - October 29 at 4:44 PM
Foghorn Therapeutics Inc.Foghorn Therapeutics Inc.
reuters.com - October 29 at 4:44 PM
DateCompanyBrokerageAction
2/8/2021AtrecaJefferies Financial GroupInitiated Coverage
8/12/2020AtrecaHC WainwrightLower Price Target
7/1/2020AtrecaCanaccord GenuityBoost Price Target
6/17/2020AtrecaCowenReiterated Rating
4/21/2020AtrecaWedbushInitiated Coverage
4/15/2020AtrecaRobert W. BairdInitiated Coverage
9/4/2019AtrecaRoth CapitalInitiated Coverage
8/20/2019AtrecaBrookline Capital ManagementReiterated Rating
7/15/2019AtrecaStifel NicolausInitiated Coverage
7/15/2019AtrecaEvercore ISIInitiated Coverage
8/18/2020Inozyme PharmaBank of AmericaInitiated Coverage
8/18/2020Inozyme PharmaPiper SandlerInitiated Coverage
11/17/2020Applied TherapeuticsBarclaysLower Price Target
10/8/2020Applied TherapeuticsTruistInitiated Coverage
4/22/2020Applied TherapeuticsThe Goldman Sachs GroupInitiated Coverage
1/27/2020Applied TherapeuticsUBS GroupBoost Price Target
1/9/2020Applied TherapeuticsCitigroupBoost Price Target
3/18/2021Selecta BiosciencesWilliam BlairUpgrade
1/26/2021Selecta BiosciencesMizuhoUpgrade
10/9/2020Selecta BiosciencesCantor FitzgeraldReiterated Rating
6/18/2020Selecta BiosciencesNeedham & Company LLCReiterated Rating
3/29/2021Foghorn TherapeuticsMorgan StanleyLower Price Target
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.